ArticleHemaSphere2026
Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies.
Jayastu Senapati, Jennifer Croden, Guillermo Garcia-Manero, Koichi Takahashi, Naval G Daver, Tapan M Kadia, Gautam Borthakur, Nicholas James Short, Elias Jabbour, Fadi Haddad and 12 more
Abstract read
In one paragraphArticle in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Guillermo Garcia-ManeroDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Koichi TakahashiDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Naval G DaverDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Tapan M KadiaDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Gautam BorthakurDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Nicholas James ShortDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Elias JabbourDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Fadi HaddadDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Prithviraj BoseDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Sanam LoghaviDepartment of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas United States.
Elizabeth J ShpallDepartment of Stem Cell Transplantation & Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas United States.
Jeremy RamdialDepartment of Stem Cell Transplantation & Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas United States.
Uday R PopatDepartment of Stem Cell Transplantation & Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas United States.
Richard E ChamplinDepartment of Stem Cell Transplantation & Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas United States.
Farhad RavandiDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Hagop M KantarjianDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Courtney D DinardoDepartment of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Prognosis in therapy-related acute myeloid leukemia (T-AML) remains poor, but understanding outcomes with venetoclax (VEN)-based therapy is relevant. We retrospectively analyzed 317 adult patients with newly diagnosed T-AML focusing on lower intensity therapy (LIT) VEN-containing regimens. Patients with an antecedent myeloid disorder before AML diagnosis were excluded. The median age was 69 years (range 21-92); 50% evaluated patients had a complex karyotype, and 40% evaluated patients had a
Identifiers
PMID41694734
PMCPMC12895360
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390